title: Visual Field Outcomes for the Idiopathic Intracranial Hypertension Treatment Trial (IIHTT).
abstract: OBJECTIVE
  The Idiopathic Intracranial Hypertension Treatment Trial (IIHTT) showed that acetazolamide provided a modest, significant improvement in mean deviation (MD). Here, we further analyze visual field changes over the 6-month study period.
  
  
  METHODS
  Of 165 subjects with mild visual loss in the IIHTT, 125 had perimetry at baseline and 6 months. We evaluated pointwise linear regression of visual sensitivity versus time to classify test locations in the worst MD (study) eye as improving or not; pointwise changes from baseline to month 6 in decibels; and clinical consensus of change from baseline to 6 months.
  
  
  RESULTS
  The average study eye had 36 of 52 test locations with improving sensitivity over 6 months using pointwise linear regression, but differences between the acetazolamide and placebo groups were not significant. Pointwise results mostly improved in both treatment groups with the magnitude of the mean change within groups greatest and statistically significant around the blind spot and the nasal area, especially in the acetazolamide group. The consensus classification of visual field change from baseline to 6 months in the study eye yielded percentages (acetazolamide, placebo) of 7.2% and 17.5% worse, 35.1% and 31.7% with no change, and 56.1% and 50.8% improved; group differences were not statistically significant.
  
  
  CONCLUSIONS
  In the IIHTT, compared to the placebo group, the acetazolamide group had a significant pointwise improvement in visual field function, particularly in the nasal and pericecal areas; the latter is likely due to reduction in blind spot size related to improvement in papilledema. (ClinicalTrials.gov number, NCT01003639.).
authors.affiliation: Department of Neurology, University of Iowa, Iowa City, Iowa, United States 2Department of Ophthalmology and Visual Sciences, University of Iowa, Iowa City, Iowa, United States.
authors.forename: Michael
authors.initials: M
authors.lastname: Wall
authors.affiliation: Department of Ophthalmology and Visual Sciences, University of Iowa, Iowa City, Iowa, United States.
authors.forename: Chris A
authors.initials: CA
authors.lastname: Johnson
authors.affiliation: Department of Ophthalmology and Vision Science, University of California Davis, Davis, California, United States.
authors.forename: Kimberly E
authors.initials: KE
authors.lastname: Cello
authors.affiliation: Department of Biostatistics, College of Public Health, University of Iowa, Iowa City, Iowa, United States.
authors.forename: K D
authors.initials: KD
authors.lastname: Zamba
authors.affiliation: Departments of Biostatistics and Computational Biology and Neurology, University of Rochester Medical Center, Rochester, New York, United States.
authors.forename: Michael P
authors.initials: MP
authors.lastname: McDermott
authors.affiliation: Department of Ophthalmology and Vision Science, University of California Davis, Davis, California, United States 6Department of Neurology and Neurological Surgery, University of California Davis, Davis, California, United States.
authors.forename: John L
authors.initials: JL
authors.lastname: Keltner
mesh_terms: D000086:Acetazolamide / Q000627:therapeutic use*; D000293:Adolescent; D000328:Adult; D002257:Carbonic Anhydrase Inhibitors / Q000627:therapeutic use; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D008297:Male; D008875:Middle Aged; D011559:Pseudotumor Cerebri / Q000175:diagnosis / Q000188:drug therapy* / Q000503:physiopathology; D013997:Time Factors; D016896:Treatment Outcome; D014792:Visual Acuity; D058609:Visual Field Tests; D014794:Visual Fields / Q000187:drug effects / Q000502:physiology*; D055815:Young Adult
chemical_list: D002257:Carbonic Anhydrase Inhibitors; D000086:Acetazolamide